Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price target of $950.00. David Risinger has given his Buy rating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback